The HOPE4MCI study: A randomized double‐blind assessment of AGB101 for the treatment of MCI due to AD

Documenti analoghi

• The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in APOE ε4 non‐carriers with mild cognitive impairment due to Alzheimer's disease
  di: Arnold Bakker, et al.
  Pubblicazione: (2024)
• The HOPE4MCI study: AGB101 treatment normalizes aberrant network activity and slows entorhinal cortex atrophy in patients with amnestic mild cognitive impairment due to Alzheimer's Disease who are ApoE‐4 non‐carriers
  di: Arnold Bakker, et al.
  Pubblicazione: (2025)
• First‐in‐human positron emission tomography study of intranasal insulin in aging and MCI
  di: Kiran K. Solingapuram Sai, et al.
  Pubblicazione: (2025)
• The HOPE4MCI study: AGB101 treatment reduces entorhinal cortex atrophy in patients with amnestic mild cognitive impairment due to Alzheimer's Disease who are ApoE‐4 non‐carriers
  di: Nisha Rani, et al.
  Pubblicazione: (2024)
• Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 years
  di: Marwan Sabbagh, et al.
  Pubblicazione: (2025)